Type 2 von Willebrand disease includes a wide range of qualitative abnormalities of von Willebrand factor structure and function resulting in a variable bleeding tendency. According to the current classification, four different subtypes can be identified, each with distinctive phenotypic and therapeutic characteristics. Current available laboratory methods allow a straightforward approach to VWD subtyping, and although the precise molecular characterization remains complex, it is not required for appropriate treatment for the vast majority of cases.
INTRODUCTION
Von Willebrand factor (VWF) is a multimeric protein synthesized by endothelial cells and megakaryocytes, required for platelet adhesion to subendothelium and platelet-to-platelet cohesion and aggregation, particularly under elevated shear stress conditions 1, 2 . VWF high molecular weight multimers (HMWM) are particularly efficient as bridging molecules, through interaction with platelet GpIb and GpIIb-III and sub-endothelial collagen 3 . VWF binds to coagulation factor VIII (FVIII), protecting it from premature proteolysis in the circulation and increasing its availability at the site of the growing platelet thrombus 4 .
Quantitative (type 1 and 3) or qualitative defect of VWF (type 2) cause von Willebrand disease (VWD), the most frequent autosomal inherited bleeding disorder 5 . Almost all cases identified by epidemiological investigations are type 1, and no data are available for type 2. Analysis of patient series registered at specialized centers shows that type 2 VWD patients are relatively rare compared to type 1 VWD patients (with a 1:3 ratio) 6 . However, they offer an extraordinary view of the clinical consequences of even tiny molecular perturbations and because of their diagnostic and therapeutic challenges.
Type 2 VWD: a heterogeneous disease subgroup
The gene coding for VWF (VWF) spans approximately 178 kilobases over 52 coding exons in the short arm of chromosome 12. After the initial identification of VWF missense mutations in exon 28 associated with type 2 VWD 7 , causative mutations for most of the other types have been identified for each VWF domain 8 ( Figure 1 ). In general, mutations responsible for type 2 are
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The most common qualitative abnormality found in type 2 VWD affects epitopes involved in binding to platelet GPIbα, an activity measurable in vitro after the addition of ristocetin and referred to as VWF Ristocetin Cofactor activity (VWF:RCo) 9 . A ratio between VWF:RCo activity and VWF antigen (VWF:Ag) below 0.6 is paradigmatic of dysfunctional type 2A and 2M
VWD. In type 2A VWD, there is a variable lack of HMWM, caused mainly by mutations in A2 domain affecting the multimerization process or susceptibility to ADAMTS-13, but also in D1/D2 multimerization regions and the C-terminal CK region. In type 2M point mutations in the A1 or, rarely, A3 domains are usually found 10 . 40, 41 .
The personal bleeding history may be of some value in guiding the optimal therapy in VWD as suggested by several clinical observations. In the European MCMDM-VWD1 Study, the bleeding score was superior to VWF measurement for the prediction of surgical bleeding 42 . In a prospective cohort of 46 patients with type 2A and 61 with type 2M VWD, patients having a BS>9 had an almost six-fold higher risk of spontaneous bleeding during follow-up than those with a normal BS 39 . Finally, in a recent large prospective investigation performed in 796 patients with all types of VWD, a BS>10 at enrolment was the strongest predictor of bleeding with a 5.5
fold increased risk during 1-year follow-up 43 .
These observations suggest that patients with significant previous bleeding history may be at higher bleeding risk. These patients may require more stringent monitoring after surgery or a bleeding episode to assure that proper therapeutic goals are achieved.
TREATMENT OF TYPE 2 VON WILLEBRAND DISEASE: A CASE BASED APPROACH
The treatment goal in type 2 VWD is to achieve and maintain adequate hemostatic levels of VWF/FVIII for the time required for tissue healing while avoiding excessive peak concentrations.
It should be remembered that while VWF activity is defective in type 2 VWD, FVIII biosynthesis is fully functional; the half-life of FVIII:C in VWD patients is usually approximately twice that
For personal use only. on January 27, 2018. by guest www.bloodjournal.org From of VWF:RCo (∼20-24 hours versus ∼10-14 hours) because of the endogenous production of FVIII 44 . Very high FVIII:C levels (> 150 IU/dL) may be achieved in the patient because of the accumulation of the infused and endogenously synthesized FVIII after closely spaced infusions 44 , possibly increasing thromboembolic risk 36, 37 . A recent systematic review of prospective studies published after 1990 showed only two documented venous thromboembolic complications and five episodes of superficial thrombophlebitis in 361 VWD patients following over 8,000 concentrate infusions 45 . We suggest monitoring trough VWF:RCo and FVIII:C plasma levels daily in this circumstances.
Desmopressin should always be considered in patients showing a good response to this agent and having minor hemorrhages or needing minor surgery. Table 2 reports the recommended interventions based on the patient clinical setting, desired through VWF levels and treatment type.
Nontransfusional treatment of type 2 VWD
Case 1. A 27-year-old man is referred for evaluation of anti-hemorrhagic prophylaxis for dental extraction. He suffered from epistaxis and gum bleeding, and was prescribed oral tranexamic acid to control nose bleeding in the past. His bleeding score was 4, according to the International Society on Thrombosis and Haemostasis bleeding assessment tool (ISTH-BAT) 46 Desmopressin is recommended for prophylaxis of non-major surgery and treatment of not lifethreatening hemorrhages in type 2 VWD variants responding to this agent ( Table 2) . We usually administer desmopressin at a 0.3 µg/kg dose for both test and therapeutic infusions, following originally proposed dosages 51, 52 . Some national guidelines recommend a capped dose of 20 µg 53 , and recent retrospective data suggest that even a capped dose of 15 µg may be useful 54 .
Desmopressin is however contraindicated in type 2B because the transient appearance or aggravation of thrombocytopenia may lead to an increased risk of bleeding. In type 2N associated
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Minor side-effects include tachycardia, headache, and flushing;
hyponatremia and fluid overload with seizures may be a risk, particularly in small children receiving repeated infusions. In these situations, serum electrolytes should be monitored and fluid intake limited 55 .
Replacement therapy for type 2 VWD
Case 2. A 4-year-old girl with VWD was referred for recurrent nosebleeds and easy bruising, totaling a BS equal to 2. In very young patients, the sensitivity of clinical assessment is (Table 3) , with a VWF/FVIII ratio close to one. A highly purified plasma VWF concentrate containing very little FVIII has also been developed for the exclusive use in VWD 56 . However, as post-infusion levels of FVIII:C rise slowly reaching a peak between 6 and 8 hours, co-administration of a priming dose of FVIII may be required if prompt hemostasis is required in patients with baseline FVIII:C levels of 30 IU/dL or lower 57 .
As reported in Table 2 , the goal of treatment in patients undergoing major surgery (or having a major bleeding) is to maintain VWF/FVIII plasma levels around 80-100 IU/dL for at least a couple of days and trough level above 50 IU/dL for an additional 5-7 days thereafter. This is usually achieved with a loading dose of 50-60 U/kg of VWF:RCo, followed by similar daily doses for the next two days 58 . VWF/FVIII concentrates are usually also labeled to their VWF:RCo content. When not, the FVIII content must be used to guide replacement therapy.
Heparin thromboprophylaxis in VWD patients undergoing major surgery is safe and is advised at least during replacement therapy when FVIII:C levels > 50 IU/dL.
Secondary long-term prophylaxis in type 2 VWD
Case 4. A 65-year-old woman with type 2B VWD associated with C1308R mutation was referred for evaluation of fatigue and dyspnea progressively increasing over the last few months. She was repeatedly treated in the past with fresh frozen plasma, cryoprecipitate and then VWF-FVIII concentrates for epistaxis, menorrhagia, bleeding at delivery and as prophylaxis prior to dental extraction and an appendectomy. At admission, her hemoglobin level was 6.5 gr/dL and mean corpuscular volume 65 fL. Serum iron and ferritin were markedly decreased. The patient reported passing black stool on some occasions during the last 1-2 months. On endoscopic examination, several small angiodysplastic malformations were evident throughout the large bowel; surgery was deemed not possible. The patient was treated with packed red cells and infusion of 50 U/kg of VWF for three consecutive days with clinical improvement. During the year following discharge, she was transfused with 54 U of packed red cells, and she was treated with >250,000 U of VWF for the same reason. The patient started prophylaxis initially with 25-40 U/kg of VWF thrice weekly for two months and then twice weekly. Over the next year, she received 6 U only of packed red cells with a consumption of 208,000 U of VWF concentrate.
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However, replacement therapy significantly reduces but does not completely abolish transfusion requirement. Prospective trials are needed to evaluate the cost-effectiveness and the improvement on patient's quality of life of prophylaxis in comparison with on-demand treatment, though clinical experience has been rated as satisfactory [65] [66] [67] . Anti-neoangiogenesis drugs (such as thalidomide), atorvastatin and octreotide could have a role as occasionally reported 68 . Use of selective VWF concentrates (e.g., Wilfactin®) may be considered for secondary prophylaxis of patients with high basal levels of FVIII, to lower thrombotic risk.
Reproductive issues in women with type 2 VWD
Case 5. A 27-year-old woman with type 2A VWD and S1506L mutation was referred at the eighth week of her first pregnancy. Her bleeding score at diagnosis was 14, and she suffered in the past for recurrent nosebleeds, menorrhagia requiring levonorgestrel to control heavy Primary post-partum bleeding is observed in up to 37.5% of type 2 women not receiving FVIII prophylaxis 69 , and special care should be taken to avoid bleeding. This is particularly relevant in the two presented patients because of their lifelong history of mucous bleeding suggesting greater bleeding risk (see "The relevance of the bleeding history in guiding the optimal therapy" above).
Pregnant VWD patients should be monitored for VWF:RCo and FVIII:C at least once during the third trimester of pregnancy. No intervention is recommended when FVIII:C and VWF:RCo levels are both around or higher than 50 IU/dL, which is always the case in type 1 VWD 70 .
However, if responsive to DDAVP, women with levels only slightly above or around 50 IU/dL may receive a single dose of desmopressin at the beginning of labor, especially if epidural anesthesia is required 70, 71 . DDAVP can also be safely used in the first trimester of pregnancy to
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In type 2A women VWF:RCo almost invariably remains reduced and substitutive treatment is required to avoid bleeding at parturition. Usually, during labor and before epidural anesthesia (if needed), 40 IU/kg of VWF are administered, followed by the same dose daily for 3-4 days, as was done in case 5 ( Table 2) . Daily monitoring of VWF:RCo level is recommended during the same period after parturition. In VWD 2B the increase of the abnormal VWF can cause or worsen thrombocytopenia 72 and platelet concentrates have been sometimes transfused. The same therapeutic schedule proposed in Table 2 is recommended. In type 2M, the abnormal VWF:RCo/VWF:Ag ratio persists throughout pregnancy, but usually VWF:RCo reaches levels greater than 50 IU/dL. Desmopressin infusion may be however considered in women with significant bleeding history, especially for previous primary or secondary post-partum bleeding.
In VWD type 2N, as shown for case 6, FVIII:C completely normalizes by the end of pregnancy, and anti-hemorrhagic treatment is seldom required.
Other than parturition, type 2 VWD women may present with several other gynecological bleeding problems. Heavy menstrual losses, particularly at menarche, may be the first relevant bleeding symptom reported and leading to VWD diagnosis 73, 74 . Midcycle pain due to bleeding into the corpus luteum after ovulation has been described in up to 49% of women with type 1 VWD 75 . Corpus luteum bleeding may extend into the broad ligament, and even cause massive haemoperitoneum requiring blood transfusion and surgical drainage 76 . In type 2 VWD women with mild gynecological bleeding, we recommend use of tranexamic acid to control menstrual
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Conclusions
An array of tests, easily available even in non-specialized laboratories, allows an accurate diagnosis and typing of the different forms of type 2 VWD. In variant forms of VWD, testing for desmopressin response is of greatest importance in either the propositus or related family members having the same VWF profile as this compound may be conveniently used to treat common minor bleeding or procedures. The bleeding history should be carefully assessed at diagnosis by using a standardized approach which may help identifying those patients at greater risk of bleeding thereafter. A high index of suspicion is however required in young patients, who may present with a silent bleeding history and minor abnormalities of the screening tests. The therapeutic armamentarium is well standardized, readily accessible (at least in Western Countries) and with a high safety profile, so that the risk of intractable bleeding because of VWF deficiency alone is exceptional. Figure   Figure 1 . Correlates between VWF molecular abnormalities, protein domain localization, laboratory phenotype and subtype classification in type 2 VWD Figure 2 . Diagnostic flow-chart for laboratory classification of type 2 VWD. Diagnosis should be considered in patients with a significant bleeding history and plasma VWF:RCo below 40 IU/dL. * denotes that VWF:Ag or VWF:CBA should be reduced proportionally to VWF:RCo. In addition to this flow-chart, type 2N should be considered in patients with a significant bleeding history and a FVIII/VWF:Ag ratio below 0.6; VWF:FVIIIB is used to differentiate from mild hemophilia A.
